Genmab — Maj 2020
-
EL we dont know yet if dara SC and ofa will be succesful launch

-
NOVO just today mentioned that thier new launch is impacted a lot due to the situation that thier sales employees can not visit
-
Thanks E L - great news

-
That could be around 15 million USD in Teppezza royalties this year
-
Lastly, on ofatumumab, that's clearly the focus, bringing a highly efficacious B-cell therapy, which is safe, which can be administered at home. And particularly now in a post-COVID period, this is going to be absolutely paramount for the market and for patients. So we're very excited about this prospect. And clearly, we're focusing for a big launch in this area.
-
I have seen analysts calculate with 6.5%
-
In Europe we are now opening up again. That includes hospitals and doctors. Therefore it should also mean opening up in Genmab related matters
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind